Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) EBITDA (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBITDA for 8 consecutive years, with $43.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA changed N/A to $43.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.9 million, a N/A change, with the full-year FY2025 number at $20.9 million, up 111.93% from a year prior.
  • EBITDA was $43.4 million for Q4 2025 at Soleno Therapeutics, up from $26.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $43.4 million in Q4 2025 to a low of -$43.9 million in Q1 2025.